Company Nuo Therapeutics Inc OTC Bulletin Board
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-20 | Nuo Therapeutics, Inc. announced that it has received $0.650875 million in funding | CI |
05-15 | Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Cell-based Technologies
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +442.12% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +442.12% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Jorden
CEO | Chief Executive Officer | 61 | 18/09/08 |
Peter Clausen
COO | Chief Operating Officer | 58 | 31/08/08 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
C. Winzer
BRD | Director/Board Member | 67 | 29/01/09 |
David Jorden
CEO | Chief Executive Officer | 61 | 18/09/08 |
Paul Mintz
BRD | Director/Board Member | 75 | 06/04/17 |
Scott Pittman
BRD | Director/Board Member | 65 | 04/05/16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 45,466,238 | 18,981,995 ( 41.75 %) | 0 | 41.75 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+18.43% | 122B | |
+19.81% | 112B | |
-23.74% | 19.33B | |
-18.45% | 16.17B | |
-19.97% | 15.6B | |
-49.33% | 14.65B | |
+57.08% | 14.34B | |
+7.95% | 14B | |
+126.04% | 11.29B |
- Stock Market
- Equities
- AURX Stock
- Stock
- Company Nuo Therapeutics Inc